Clinical Trial: Protein Biomarker Levels in Tissue Samples From Young Patients With Low-risk Hodgkin Lymphoma

Study Status: Completed
Recruit Status: Completed
Study Type: Observational

Official Title: Investigation to Evaluate the Levels of Human Germinal-center-Associated Lymphoma (HGAL) Protein in Pediatric Hodgkin Lymphoma and Correlate With Early Response

Brief Summary:

RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors identify and learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment.

PURPOSE: This research trial is studying protein biomarker levels in tissue samples from young patients with low-risk Hodgkin lymphoma.


Detailed Summary:

OBJECTIVES:

  • To investigate the variability of expression of human geminal-center-associated lymphoma (HGAL) protein in pediatric low-risk Hodgkin lymphoma.
  • To assess the variability of HGAL staining between risk groups by comparing samples from subjects enrolled in the low-risk study AHOD0431 with subject samples enrolled in AHOD0031 for intermediate-risk classical Hodgkin Lymphoma (cHL).
  • To assess the variability of HGAL staining by evaluating a tissue array created from subjects with intermediate-risk cHL.
  • To correlate rapid or slow early-response in the intermediate-risk group with HGAL protein expression.

OUTLINE: Paraffin-embedded tissue samples and tissue microarrays are analyzed for protein expression by IHC.


Sponsor: Children's Oncology Group

Current Primary Outcome:

  • Variability of HGAL protein expression in pediatric patients with low-risk classical Hodgkin lymphoma (cHL)
  • Variability of HGAL staining between low-risk and intermediate-risk pediatric patients with cHL
  • Variability of HGAL staining as assessed by tissue array in pediatric patients with intermediate-risk cHL
  • Correlation of rapid or slow early response in the intermediate-risk group with HGAL protein expression


Original Primary Outcome: Same as current

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Children's Oncology Group

Dates:
Date Received: June 2, 2011
Date Started: May 2011
Date Completion:
Last Updated: May 13, 2016
Last Verified: May 2016